Matias Serebrinsky

Investor in brain and mental health @psymedventures. Co-host Still figuring it all out.

[Matias Serebrinsky @matisere]

Amazing brain data resource from Crownlands!

[Nate Dalva @dalvabaird]

Human biology matters. Scientists and AI need human data to understand health and disease.

Crownlands is open sourcing Gateway 4M, the largest single-cell tissue dataset ever released from living humans, to advance research on brain aging and neurodegeneration.

[Jack O'Meara @Jack_O_Meara]

Opening new R&D site in Boston as folks move to China. Continue to believe US is best place in world for novel platform innovation, and UK for discovery biology.

https://t.co/dlJrUvPQRK

[Nate Dalva @dalvabaird]

New AI x Science research:

Frontier models have gaps in their scientific knowledge. Our new eval tests how models recall significant published findings without tools, in Alzheimer’s disease.

GPT-5.5 performed best among released models, but the benchmark remains far from saturated.

Questions are based on prominent findings, often the central claims from highly cited papers, that were published before the models’ cutoff dates.

Does it impact AI x Science discovery agents? In the topics that the LLMs have gaps in “parametric” knowledge, agents using the model overlook potential discoveries -- even with tools and internet search.

The conclusion: training models more intensively on the latest scientific findings is a promising way to make scientific agents more useful!

“More information can be pulled into context. More information should be pulled into context. But there will always be a marginal query that the agent does not run, and the shape of this frontier is determined by internal knowledge.”

Link to research blog below:

[Greg Kubin @kubeans]

1 month in space ages a brain organoid 10 years on Earth. Alysson Muotri's lab at UCSD is using this insight to study neurological disease. In our latest BT epi, we discuss aging the brain in orbit and what brain organoids might mean for the future of AI.

link in comments!

[Matias Serebrinsky @matisere]

@NateTepper Congrats Nate! What a journey it's been since Humans Anon. You're a top 0.1% in drive and optimism.

[Nate Tepper @NateTepper]

We’ve raised $12M to hire the next generation of filmmakers at TrueShort!

Led by Keith Rabois at Khosla Ventures and participation from Jeffrey Katzenberg (Dreamworks), Ravi Nandan (A24), Scott Belsky (Behance), General Catalyst, and more

Here’s the story 👇

[Jacob Robinson @JTRobinsonLab]

Thanks to @emilylmullin at @WIRED for taking some time to chat with us about our recent approval to start a clinical trial! Exciting year for #BCI !!

[Matias Serebrinsky @matisere]

Love these guys

[Rod @rod_mallo]

if you come across this founder, don't believe a word he says

[Matias Serebrinsky @matisere]

Gilgamesh sold a psychedelic drug to AbbVie for up to $1.2B.

We’ll look back on this as a landmark moment in psychedelic therapeutics and experiential therapies more broadly.

For the first time, Gilgamesh CEO & co-founder Jonathan talks on a podcast about the journey.

Listen: https://t.co/lhZPmlbBDX

[PsyMed Ventures @PsymedVentures]

NYC! Join us April 2 for a PsyMed Ventures neuro event, part of New York Deep Tech Week.
Featuring:
@MeganBlewett RNAi therapeutics & brain reprogramming
Dr. Ann DeSollar blindfold vision (+ live demo) @MindSeeIt
@BobbyKasthuri whole-brain emulation

RSVP in 🧵

[Matias Serebrinsky @matisere]

Congrats @PsymedVentures portco Aerska! @Jack_O_Meara has made so much progress in a short time.

[Alex Colville @AlexJColville]

Very happy to share that we co-led Aerska's $39M Series A with @eqt's Dementia Fund! Neurodegeneration has robbed us of too much. Time to fight back!! $60M to date for Aerska by @Jack_O_Meara in just a couple months over one year of existing! We movin.

[Mgoes (bio/acc 🤖💉) @m_goes_distance]

we're only 3 weeks into 2026

and we've got:

- grey-market peptides going mainstream
- psychedelics in Phase III trials
- OpenAI Health
- Claude for Healthcare
- GLP-1s evolving beyond diabetes/obesity
- gene editing expanding in Singapore, China
- AI designing proteins in minutes
- longevity biomarkers becoming consumer products
- DeSci funding real research outside institutions
- biohacking shifting from fringe to default

forget software, biotech will define this decade.

[signüll @signulll]

the winner of health + ai will look like:

“i understand you better than your doctor,
i notice patterns you can’t see,
i tell you why things matter,
i help you act today,
i make it feel worth doing tomorrow.”

biggest market on earth. infinite edge cases.

[Mark Jacobstein @mjacobstein]

On the new episode of Neural Compass, @kubeans and @matisere from @PsymedVentures join me to trace their journey from tech founders to frontier investors betting on the brain.

[Matias Serebrinsky @matisere]

One of the biggest bottlenecks in neuro has been getting drugs into the brain. It sounds simple, but it has blocked a ton of innovation and is one of the core reasons progress in brain health has lagged behind other fields.

New approaches called brain shuttles are starting to change that, and it feels like a real unlock for the century of the brain.

Just dropped a new epi diving into this with @JimGormanMDPhD from the @wyssinstitute.

Listen here: https://t.co/CeG7FU4DQS

[Matias Serebrinsky @matisere]

I get why there aren't more drugs for human enhancement available, things like attention, vigilance, and stress resilience. Outside of people with neurological disorders, our brains are already super optimized. Evolution did a great job over millions of years.

But things are just different today. I wish there were way more efforts. Evolution didn't optimize our bodies for modern conditions, like sleep loss, circadian misalignment, chronic high-threat/stress situations, and needing to stay alert for a long time.

We could focus on learning from specific genotypes that don't suffer from the things most of us do like short-sleepers, or borrow from other species like the gila monster and GLP1s, or build a neuro enhancement-first discovery platform tuned to gains in healthy people.

Reach out if you want to discuss. We have lots of ideas (and opinions) at PsyMed.

[Matias Serebrinsky @matisere]

I get why there aren't more drugs for human enhancement available, things like attention, vigilance, and stress resilience. Outside of people with neurological disorders, our brains are already super optimized. Evolution did a great job over millions of years.

But things are just different today. I wish there were way more efforts. Evolution didn't optimize our bodies for modern conditions, like sleep loss, circadian misalignment, chronic high-threat/stress situations, and needing to stay alert for a long time.

We could focus on learning from specific genotypes that don't suffer from the things most of us do like short-sleepers, or borrow from other species like the gila monster and GLP1s, or build a neuro enhancement-first discovery platform tuned to gains in healthy people.

Reach out if you want to discuss. We have lots of ideas (and opinions) at PsyMed.

[Matias Serebrinsky @matisere]

Thrilled to back Aerska! RNAi for neurodegenrative conditions is moving from sci-fi to near-term reality. Delivery is one of the big unlocks, and Aerska’s antibody-oligo brain shuttle approach to cross the BBB and get inside neurons is super compelling. Sharp science and clear execution by Jack O'Meara and a star team.

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO @Jack_O_Meara explains.

Full video: https://t.co/edPHLpIpwa

[the residency @theresidency]

Matias Serebrinksky stopped by our @inventorsRes today 🪽

Matias is the founding partner of @PsymedVentures, a venture fund that backs frontier neuroscience tech
@mianirtizaaftab

[PsyMed Ventures @PsymedVentures]

Why Cracking the Brain Is Harder Than Curing Cancer — Until Now...

Listen to the full episode:

https://t.co/F6JZCSv8kD